Summary
Sixteen heavily pretreated patients with advanced intermediate and high-grade diffuse non-Hodgkin's lymphoma (NHL) were treated with 260 mg/M2 of bisantrene every three weeks. Thirty infusions of bisantrene were given without evidence of objective response. Pain in the infused arm, with or without signs of phlebitis, was the most common side effect occurring in 40% of treated patients. At the doses employed bisantrene had little activity as a single agent in this group of previously treated patients with unfavorable histology NHL.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bowden GT, Garcia D, Peng YM, Alberts DS: Molecular pharmacology of the anthracycline drug 9,10-anthracenedi-carboxaldehyde bis[(4,5 dihydro-1H-imidazol-2-yl) hydrazone] dihydrochloride (CL 216,942). Cancer Res 42:2660–2665, 1982
Citarella RV, Wallace RE, Murdock KC, Angier RB, Durr FC: Antitumor activity of CL 216,942 9,10-anthracenedicarboxaldehyde bis [(4,5 dihydro-1 H-imidazol-2-yl) hydrazone] dihydrochloride. Abstracts of the 20th Interscience Conference on Antimicrobial Agents and Chemotherapy, September, 1980. Abstract 23
Sparano BM, Gordon G, Hall C, Iatropoulos MJ, Noble TF: Assessment of cardiotoxic potential of a new anticancer compound, an anthracenebishydrazone derivative in beagle dogs. Comparison with Adriamycin. Abstracts of the 20th Interscience Conference on Antiomicrobial Agents and Chemotherapy. September, 1980. Abstract 31
Jones SE, Grozea PN, Metz EN, et al.: Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma — a Southwest Oncology Group study. Cancer 43:417–425, 1979
The Non-Hodgkin's Lymphoma Pathologic Classification Project Writing Committee: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphoma. Cancer 49:2112–2135, 1982
Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M: Report of the committee on Hodgkin's disease staging classification. Cancer Res 31:1860–1861, 1971
Von Hoff DD, Myers JW, Kuhn J, Sandbach JF, Pocelinko R, Clark G, Coltman CA: Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis [(4,5 dihydro-1H-imidazol-2-yl) hydrazone] dihydrochloride (CL 216,942). Cancer Res 41:3118–3121, 1981
Alberts DS, Mackel C, Pocelinko R, Salmon SE: Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis [(4,5-dihydro-1H-imidazol-2-yl) hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay. Cancer Res 42:1170–1175, 1982
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Miller, T.P., Jones, S.E., Alberts, D.S. et al. Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas. Invest New Drugs 2, 75–77 (1984). https://doi.org/10.1007/BF00173790
Issue Date:
DOI: https://doi.org/10.1007/BF00173790